Diabetes and Obesity Drug Discovery & Therapy (Track)
Rare Sugar D-Psicose Ameliorates Glucose Intolerance Through The Activation Of Liver Glucokinase And Prevention Of Pancreatic Islet Injury In Type 2 Diabetic Otsuka Long-Evans Tokushima Fatty (Oletf) Rats
Mohammad Akram Hossain
Cell Physiology Department, Kagawa University, Shikoku Island, Kagawa; Japan
Abstract:
Introduction: Prevalence of obesity becomes the most alarming health problem in the present world. Obese humans and experimental animals manifest hyperinsulinemia, hyperlipidemia and insulin resistance, predisposing them to glucose intolerance and diabetes.
We introduce a rare sugar, D-psicose which has been shown to reduce hyperglycemia, hyperlipidemia and abdominal fat deposition in non-diabetic rats experimentally, and elevated plasma glucose after glucose load clinically. In the present study, effect of D-psicose on glucose intolerance during the development of diabetes in OLETF rats, an animal model of human type 2 diabetes and obesity was investigated.
Methods and Results: Treated rats were fed 5% D-psicose in drinking water for 13 weeks and the results were compared with the control rats. D-psicose significantly reduced hyperglycemia, hyperinsulinemia, body weight gain, and food intake. Blood glucose and insulin levels were also reduced significantly after oral glucose load, possibly through the activation and translocation of liver glucokinase.
D-psicose also protected the pancreas, by the attenuation of b-cell injury evaluated by HE and Masson's trichrome staining and by the protection of islet disorganization evaluated by TGF-b and a-SMA immunostaining.
Conclusion: D-psicose, a non-calorie monosaccharide, could be a beneficial sweetener for diabetic and obese patients.
